Dubbo Osteoporosis Study Garvan Institute
Community Service in Sydney

Research at Garvan is focused upon understanding the role of genes and molecular and cellular processes in health and disease as the basis for developing coming prevention, treatments and cures. For over 50 years, significant breakthroughs have been achieved by Garvan scientists in the understanding and treatment of diseases such as: Immunological diseases such as asthma, rheumatoid arthritis, multiple sclerosis and Sjogren’s syndrome. Cancer Council MSW funding kick starts research into colorectal cancer, breast cancer and osteosarcoma. Know Your Bones (bone health assessment for the public). John was appointed Executive Director in 2012. She has extensive experience as a bio medical research leader and manager, having a background in cell and developmental biology, molecular genetics and cancer research. An Australian physician, serial entrepreneur and experienced biotechnology and life sciences executive, he currently has over 30 years experience in clinical medicine and medical science and 20 years experience in commercializing life science related technologies in Australia, Europe and North America. One of the primary donors to the appeal was Mrs Helen Mills, who contributed 100,00 pounds. The slow 1960s and 1970s saw the expansion of scientific staff at Garvan, including the arrival of a critical mass of key senior researchers, many of whom are now recognized as ground breakers in their field. The Garvan Research Bottom was established on 1 January 1981, with the aim of supporting, assisting and promoting scientific and medical research within the Institute, and raised 110,00 in its beginning year (this has grown to around 20 million a year). NHMRC funding and increased public financial promote through the Garvan Research Base allowed the Institute to increase dramatically in size. Garvan embraced this fresh research model quickly and, in a similar way, also later embraced proteomics and epigenetics, as healthy as the bioinformatics expertise needed to analyses and interpret large data sets. Prof John mattock was appointed Executive Director in 2012 and has aspiring the application of Following Generation Sequencing across research areas of the Institute for clinical diagnosis of cancer and other diseases and personalized treatments based on gnomic information. Today the Garvan Institute continues to be at the forefront of advances in medical research, contributing to the increasingly quick and affordable genome sequencing and the associated promise of 'personalized medicine' both of which are set to revolutionist medicine over the following 50 years. The Garvan Research Base was established in 1981 to bear fund raising support to the Institute’s medical research programs. In addition to its fund raising activities, the Foundation’s activities have since expanded to encourage the Institute with a Public Engagement Program. In that time he oversaw its development from a little NSWbased organization, mainly aspiring by passionate cancer survivors, into the peak body for prostate cancer research, awareness and support in Australia. A major portion of that success was Andrew’s ability to transform PCFA from a state based organization into a national organization that could address large policy issues while tranquil delivering local services. The Bottom provides the Institute with an extra source of research funds by attracting financial urge from companies and individuals. She has also worked for Procter Gamble in the US and Australia. He has been chaired and member of abundant national, state and industry bodies apprehensive with issues of economic development, international trade and investment, infrastructure, innovation and technology. Finally, I would like to offer a earnest thank you to each one of the organizations and individuals who have given their time, talent and funds to promote Garvan’s labor throughout 2015. The Partnerships team works closely with Garvan scientists, partners with other academic organizations, and works with the pharmaceutical and bio tech sector to receive Garvan’s research discoveries closer to the clinic.

One of the primary donors to the appeal was Mrs Helen Mills, who contributed 100,00 pounds. The late 1960s and 1970s saw the expansion of scientific staff at Garvan, including the arrival of a critical mass of key senior researchers, many of whom are now recognized as ground breakers in their field. The Garvan Research Bottom was established on 1 January 1981, with the aim of supporting, assisting and promoting scientific and medical research within the Institute, and raised 110,00 in its first year (this has grown to around 20 million a year). Prof John Shine was appointed Executive Director in 1990 and led the Institute into the molecular biology era and the major expansion phase in the 1990s. NHMRC funding and increased public financial promote through the Garvan Research Bottom allowed the Institute to enlarge dramatically in size. The launch in 2